Hanmi Pharmaceutical Co. Ltd. is developing a SOS1 inhibitor, HM-99462, and recently divulged results of initial preclinical studies. SOS1 is a guanine nucleotide exchange factor (GEF) that activates ...

Hence the suggestion that EGFR inhibition may act through 2 steps, the indirect angiostatic effect (in VEGF) and a direct antiangiogenic activity (in endothelial cells), in synergy with endostatin.